This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Casgevy, the commercial product formerly known as exa-cel, is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a laboratory, with the modified cells then infused back into the patient after conditioning treatment to prepare the bone marrow.
Global Genes is a rare disease umbrella organization dedicated to eliminating the burdens and challenges of rare diseases for patients and families globally. There were many impactful insights shared from the several sessions and amazing conversations at the #WeekInRare, but the top themes I took away are: 1.
The field of cell and genetherapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines.
Technologies like CRISPR-Cas9 have revolutionized the potential for geneediting, offering hope for curative treatments for conditions like Duchenne muscular dystrophy (DMD) and certain types of inherited blindness. Both therapies were awarded their approvals on the same day in December 2023.
Vittoria Biotherapeutics is a clinical-stage cell therapy company that incorporates the latest advancements in cell therapy and geneediting with a unique approach that potentially overcomes some of the issues with this therapeutic modality. So that’s really exciting,” Dr. Siciliano explained.
In a recent episode of WCG Talks Trials, WCG experts explored topics like the importance of community engagement, the latest developments in gene and cell therapies, and the challenges of clinicalresearch in rare and chronic diseases like sickle cell disease and melanoma.
This research community is exploring diverse therapeutic avenues and creative thinking, including genetherapies, cell therapies, immunotherapies, novel drug candidates, and the repurposing of drugs from other indications. For a more in-depth discussion on challenges and solutions to ALS research, read our blog.
This level of homogeneity within the clinical trial population may prevent the identification of variable therapy responses within population subgroups. In addition, safety oncology and immunotherapy, which is a focus area for Cerba Research has close ties to virology. The technology platforms are almost the same.
Pediatric cancer care has traditionally relied on chemotherapy, radiation and surgery, but emerging therapies are expanding possibilities. While obstacles such as delivery barriers, immune responses and regulatory approvals remain, clinical trials are refining these approaches, bringing hope for more effective and less toxic therapies.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content